Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMTI NASDAQ:ARQT NASDAQ:CARA NASDAQ:OLMA NASDAQ:ZEAL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/AARQTArcutis Biotherapeutics$15.40-3.1%$13.91$7.86▼$17.75$1.90B1.772.15 million shs1.64 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,155 shs237,144 shsOLMAOlema Pharmaceuticals$4.59-5.0%$4.57$2.86▼$16.62$330.48M1.9819,895 shs344,266 shsZEALZealand Pharma A/S$17.59$17.67$9.93▼$32.94$818.60M1.454,965 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%ARQTArcutis Biotherapeutics+5.93%+18.75%+18.39%+20.55%+49.72%CARACara Therapeutics0.00%0.00%0.00%0.00%+25.66%OLMAOlema Pharmaceuticals+3.87%+8.54%+15.83%+14.73%-60.73%ZEALZealand Pharma A/S0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMTIApplied Molecular TransportN/AN/AN/AN/AN/AN/AN/AN/AARQTArcutis Biotherapeutics1.2684 of 5 stars2.41.00.00.02.51.70.6CARACara Therapeutics0.2197 of 5 stars0.00.00.04.20.00.80.0OLMAOlema Pharmaceuticals2.4317 of 5 stars3.51.00.00.02.72.50.6ZEALZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTIApplied Molecular Transport 0.00N/AN/AN/AARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8022.08% UpsideCARACara Therapeutics 0.00N/AN/AN/AOLMAOlema Pharmaceuticals 3.00Buy$24.50433.77% UpsideZEALZealand Pharma A/S 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ARQT, ZEAL, AMTI, OLMA, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/14/2025OLMAOlema PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.005/14/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.004/28/2025OLMAOlema PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/AARQTArcutis Biotherapeutics$196.54M9.34N/AN/A$1.35 per share11.41CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/AZEALZealand Pharma A/S$46.54M17.59N/AN/A$3.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/AARQTArcutis Biotherapeutics-$140.04M-$1.040.00N/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AOLMAOlema Pharmaceuticals-$129.47M-$2.010.00N/AN/AN/A-42.31%-38.32%8/5/2025 (Estimated)ZEALZealand Pharma A/S-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/ALatest ARQT, ZEAL, AMTI, OLMA, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025OLMAOlema Pharmaceuticals-$0.44N/AN/AN/AN/AN/A5/13/2025Q1 2025OLMAOlema Pharmaceuticals-$0.49-$0.36+$0.13-$0.36N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTIApplied Molecular TransportN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AZEALZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTIApplied Molecular TransportN/A4.994.99ARQTArcutis Biotherapeutics0.753.553.37CARACara TherapeuticsN/A4.774.71OLMAOlema PharmaceuticalsN/A15.2215.22ZEALZealand Pharma A/S0.934.794.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTIApplied Molecular Transport41.79%ARQTArcutis BiotherapeuticsN/ACARACara Therapeutics44.66%OLMAOlema Pharmaceuticals91.78%ZEALZealand Pharma A/S1.73%Insider OwnershipCompanyInsider OwnershipAMTIApplied Molecular Transport15.90%ARQTArcutis Biotherapeutics9.40%CARACara Therapeutics3.10%OLMAOlema Pharmaceuticals16.36%ZEALZealand Pharma A/S2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableOLMAOlema Pharmaceuticals7068.42 million57.23 millionOptionableZEALZealand Pharma A/S35546.54 million45.51 millionNot OptionableARQT, ZEAL, AMTI, OLMA, and CARA HeadlinesRecent News About These CompaniesZealand Pharma A/S. (ZLDPF) Institutional Holdings | NasdaqJuly 11, 2025 | nasdaq.comZealand Pharma A/S. (ZLDPF) Analyst Research | NasdaqJuly 11, 2025 | nasdaq.comStock Movers: Sainsbury's, Zealand Pharma, Taylor WimpeyJuly 1, 2025 | bloomberg.comZealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for MoreJune 20, 2025 | biospace.comBPositive results for Zealand’s GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | thepharmaletter.comTProthena to lay off majority of staff; Zealand shares obesity drug dataJune 20, 2025 | biopharmadive.comBZealand Pharma’s 46% Stock Slump Makes New Obesity Drug CriticalJune 20, 2025 | bloomberg.comZealand Pharma announces positive topline results from phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 20, 2025 | pharmabiz.comPZealand’s GLP-2 candidate shows early weight loss resultsJune 18, 2025 | statnews.comSZealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeksJune 18, 2025 | fiercebiotech.comFZealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideJune 18, 2025 | globenewswire.comZealand Pharma increases its share capital as a result of the exercise of employee warrantsJune 6, 2025 | globenewswire.comZealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndromeJune 2, 2025 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMay 27, 2025 | globenewswire.comEuropean stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%May 26, 2025 | msn.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comZealand Pharma Appoints Chief Development OfficerMay 20, 2025 | contractpharma.comCZealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development OfficerMay 19, 2025 | globenewswire.comZealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is PriceyMay 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARQT, ZEAL, AMTI, OLMA, and CARA Company DescriptionsApplied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.Arcutis Biotherapeutics NASDAQ:ARQT$15.40 -0.50 (-3.14%) Closing price 04:00 PM EasternExtended Trading$15.29 -0.11 (-0.71%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Olema Pharmaceuticals NASDAQ:OLMA$4.59 -0.24 (-4.97%) Closing price 04:00 PM EasternExtended Trading$4.71 +0.12 (+2.61%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Zealand Pharma A/S NASDAQ:ZEALZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
